已入深夜,您辛苦了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!祝你早点完成任务,早点休息,好梦!

RIBBON-1: Randomized, Double-Blind, Placebo-Controlled, Phase III Trial of Chemotherapy With or Without Bevacizumab for First-Line Treatment of Human Epidermal Growth Factor Receptor 2–Negative, Locally Recurrent or Metastatic Breast Cancer

医学 表阿霉素 内科学 多西紫杉醇 环磷酰胺 转移性乳腺癌 危险系数 化疗 队列 肿瘤科 卡培他滨 蒽环类 贝伐单抗 乳腺癌 胃肠病学 外科 癌症 置信区间 结直肠癌
作者
Nicholas J. Robert,Véronique Dièras,John A. Glaspy,Adam Brufsky,Igor Bondarenko,Oleg Lipatov,Edith A. Perez,Denise A. Yardley,Stephen Chan,Xian Zhou,S. Phan,Joyce O’Shaughnessy
出处
期刊:Journal of Clinical Oncology [Lippincott Williams & Wilkins]
卷期号:29 (10): 1252-1260 被引量:1073
标识
DOI:10.1200/jco.2010.28.0982
摘要

PURPOSE: This phase III study compared the efficacy and safety of bevacizumab (BV) when combined with several standard chemotherapy regimens versus those regimens alone for first-line treatment of patients with human epidermal growth factor receptor 2-negative metastatic breast cancer. PATIENTS AND METHODS: Patients were randomly assigned in 2:1 ratio to chemotherapy plus BV or chemotherapy plus placebo. Before random assignment, investigators chose capecitabine (Cape; 2,000 mg/m(2) for 14 days), taxane (Tax) -based (nab-paclitaxel 260 mg/m(2), docetaxel 75 or 100 mg/m(2)), or anthracycline (Anthra) -based (doxorubicin or epirubicin combinations [doxorubicin/cyclophosphamide, epirubicin/cyclophosphamide, fluorouracil/epirubicin/cyclophosphamide, or fluorouracil/doxorubicin/cyclophosphamide]) chemotherapy administered every 3 weeks. BV or placebo was administered at 15 mg/kg every 3 weeks. The primary end point was progression-free survival (PFS). Secondary end points included overall survival (OS), 1-year survival rate, objective response rate, duration of objective response, and safety. Two independently powered cohorts defined by the choice of chemotherapy (Cape patients or pooled Tax/Anthra patients) were analyzed in parallel. RESULTS: RIBBON-1 (Regimens in Bevacizumab for Breast Oncology) enrolled 1,237 patients (Cape cohort, n = 615; Tax/Anthra cohort, n = 622). Median PFS was longer for each BV combination (Cape cohort: increased from 5.7 months to 8.6 months; hazard ratio [HR], 0.69; 95% CI, 0.56 to 0.84; log-rank P < .001; and Tax/Anthra cohort: increased from 8.0 months to 9.2 months; HR, 0.64; 95% CI, 0.52 to 0.80; log-rank P < .001). No statistically significant differences in OS between the placebo- and BV-containing arms were observed. Safety was consistent with results of prior BV trials. CONCLUSION: The combination of BV with Cape, Tax, or Anthra improves clinical benefit in terms of increased PFS in first-line treatment of metastatic breast cancer, with a safety profile comparable to prior phase III studies.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
leiyuekai完成签到 ,获得积分10
刚刚
FashionBoy的应助被chy采纳,获得10
1秒前
1秒前
斯文败类的应助被热心的明辉采纳,获得10
3秒前
3秒前
星尘完成签到 ,获得积分10
3秒前
3秒前
4秒前
烟花的应助被qianzhihe采纳,获得10
5秒前
liang发布了新的文献求助10
6秒前
Jasper的应助被almost采纳,获得10
8秒前
机智的白卉的应助被almost采纳,获得10
8秒前
Inevitable发布了新的文献求助10
8秒前
科研通AI6.3的应助被almost采纳,获得10
8秒前
慕青的应助被almost采纳,获得10
9秒前
今后的应助被almost采纳,获得10
9秒前
NexusExplorer的应助被晚风采纳,获得10
10秒前
10秒前
娇气的太阳完成签到,获得积分20
10秒前
香蕉觅云的应助被nap采纳,获得10
12秒前
12秒前
ChenH97完成签到 ,获得积分10
12秒前
13秒前
14秒前
wanci的应助被怀瑾握于丶采纳,获得10
14秒前
CodeCraft的应助被腼腆的立诚采纳,获得10
14秒前
16秒前
TreasureY发布了新的文献求助10
17秒前
活泼的夜云完成签到 ,获得积分10
18秒前
18秒前
neuroman发布了新的文献求助10
18秒前
19秒前
20秒前
21秒前
22秒前
李明之发布了新的文献求助10
23秒前
23秒前
chy发布了新的文献求助10
24秒前
sci2025opt完成签到 ,获得积分10
25秒前
禾电发布了新的文献求助10
28秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8184686
求助须知:如何正确求助?哪些是违规求助? 9573640
关于积分的说明 21832630
捐赠科研通 7782020
什么是DOI,文献DOI怎么找? 3434404
关于科研通互助平台的介绍 2558513
邀请新用户注册赠送积分活动 2481010